BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Positive Avian Flu Trial Data Using Isconova's Matrix M(TM) Published


8/29/2011 9:05:43 AM

UPPSALA, 29 August, 2011 -- Isconova AB, a leading international vaccine adjuvant company, is pleased to note that the scientific journal Vaccine has published online, the first article presenting data from the human PanFluVac trial. The phase I clinical study evaluated the safety and the immunogenicity of an avian flu vaccine adjuvanted with Matrix M™. Isconovas Matrix M™ showed excellent results in the study.

A total of 60 healthy volunteers took part in the study which was conducted at The Gade Institute, University of Bergen, Norway and funded by the European Commission through the PanFluVac research consortium. The volunteers were vaccinated with the virosomal vaccine alone or with three different doses of the vaccine formulated with Matrix M™. Earlier studies have shown that it is difficult to achieve a good immune response against avian flu.

Matrix M™ increased the efficacy of the vaccine considerably and the adjuvanted vaccines met all the efficacy criteria of the study. In the article the authors commented*; “In conclusion, in this phase I clinical trial the Matrix M™ adjuvanted vaccine was shown to be well-tolerated and effective at enhancing both the homologous and heterologous antibody responses to pandemic influenza viruses. Furthermore, Matrix M™ is a promising adjuvant for the formulation of pandemic vaccines, enabling enhanced antibody responses and allowing dose sparing down to 1.5µg HA.”

Lena Söderström, CEO of Isconova, commented;

“The PanFluVac trial was a major milestone for Isconova as it was the first time Isconova’s adjuvant Matrix M™ was tested in humans. There is a clear unmet medical need for better and more effective vaccines, and the excellent results of the PanFluVac trial is further evidence that Matrix M™ can address this important market.”

For more information, please contact:

Lena Söderström, CEO Isconova

Tel +46 70-816 39 12, e-mail: lena.soderstrom@isconova.com

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.

Isconova was listed on NASDAQ OMX First North (ticker: ISCO) in November 2010. E. Öhman J:or AB is the Company’s Certified Adviser. www.isconova.com

About PanFluVac

PanFluVac is a European Commission funded research consortium for development of efficacious vaccine formulation systems for prophylactic control of influenza pandemics. www.panfluvac.org

*Cox RJ, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine (2011), doi:10.1016/j.vaccine.2011.08.042


Read at BioSpace.com


   
Influenza
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->